A View from the Wellcome Trust Drug-Resistant Infections Priority Programme: Creating a Sustainable Research and Development Ecosystem to Meet the Global Need for Antibiotics

  15 June 2020

Antibiotics have been a key component of modern medicine for decades. A critical question is why not enough antibacterials are being developed to tackle the growing challenge of drug-resistant infections. While current innovation in the early preclinical pipeline is encouraging, the journey for any new antibiotic is burdened with multiple challenges across its early and late development path. In this viewpoint, we explore the barriers to antibiotic development and how the Wellcome Trust is addressing these problems and working toward developing long-term solutions to facilitate a sustainable R&D ecosystem.

Further reading: ACS Publications
Author(s): Joanna Wiecek and Gemma Buckland-Merrett
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





EADA 2023

Emerging Antimicrobials and Diagnostics in AMR 2023

International Matchmaking Symposium EADA 2023
Amsterdam, The Netherlands
16/17 November

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!